Scarica l'app Stockscreener
15.56
2.57%
0.39
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$15.17
Aprire:
$15.41
Volume 24 ore:
674.95K
Relative Volume:
1.33
Capitalizzazione di mercato:
$631.98M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-3.0331
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
+7.46%
1M Prestazione:
+13.33%
6M Prestazione:
+41.20%
1 anno Prestazione:
-65.22%
Intervallo 1D:
$15.15
$15.81
Intervallo di 1 settimana:
$14.04
$15.81
Portata 52W:
$9.12
$72.37
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
15.56 | 589.74M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
Connor Clark & Lunn Investment Management Ltd. Acquires 98,957 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Tejara Capital Ltd Takes $410,000 Position in Keros Therapeutics, Inc. $KROS - MarketBeat
Keros Therapeutics Gains FDA Orphan Drug Designation - TipRanks
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - Seeking Alpha
Keros Therapeutics Receives FDA Orphan Drug Designation for KER-065 in Duchenne Muscular Dystrophy Treatment - Quiver Quantitative
Keros Announces U.S. FDA Orphan Drug Designation Granted to - GlobeNewswire
FDA Grants Special Status to New Duchenne Muscular Dystrophy Drug: Keros' KER-065 Gets Orphan Designation - Stock Titan
Keros Therapeutics Inc. Tests 50 Day MA After Sharp DeclinePortfolio Gains Report & Low Risk High Reward Trade Ideas - thegnnews.com
Keros Therapeutics Inc. Building a Base Near SupportJuly 2025 Technicals & Trade Opportunity Analysis - newsyoung.net
How to build a dashboard for Keros Therapeutics Inc. stockTrade Risk Assessment & Low Risk High Reward Ideas - Newser
Applying Elliott Wave Theory to Keros Therapeutics Inc.Dip Buying & High Accuracy Swing Entry Alerts - Newser
Applying sector rotation models to Keros Therapeutics Inc.Market Trend Review & High Conviction Buy Zone Alerts - Newser
Why Keros Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Volume & Growth Focused Stock Reports - Newser
Is Keros Therapeutics Inc. forming a breakout pattern2025 Risk Factors & Consistent Income Trade Recommendations - thegnnews.com
Is Keros Therapeutics Inc. showing signs of accumulation2025 Key Lessons & Low Risk High Win Rate Stock Picks - Newser
Using data tools to time your Keros Therapeutics Inc. exitMarket Growth Review & Low Risk High Reward Ideas - Newser
What makes Keros Therapeutics Inc. stock price move sharply2025 Key Lessons & Weekly High Return Stock Opportunities - thegnnews.com
Does Keros Therapeutics Inc. qualify in momentum factor screeningDay Trade & Community Consensus Stock Picks - Newser
Will Keros Therapeutics Inc. continue its uptrend2025 Stock Rankings & Safe Entry Trade Reports - Newser
Is this a good reentry point in Keros Therapeutics Inc.Quarterly Trade Report & Weekly Momentum Picks - Newser
Key metrics from Keros Therapeutics Inc.’s quarterly dataPortfolio Return Report & Technical Entry and Exit Tips - Newser
Signal strength of Keros Therapeutics Inc. stock in tech scannersEarnings Recap Report & Daily Profit Maximizing Tips - Newser
Applying chart zones and confluence areas to Keros Therapeutics Inc.Entry Point & Community Trade Idea Sharing Platform - Newser
Combining price and volume data for Keros Therapeutics Inc.July 2025 Analyst Calls & Safe Capital Growth Plans - Newser
Is Keros Therapeutics Inc. stock trending bullish2025 Winners & Losers & Target Return Focused Picks - thegnnews.com
Can Keros Therapeutics Inc. hit a new high this monthForecast Cut & Free Weekly Chart Analysis and Trade Guides - Newser
Exit strategy if you’re trapped in Keros Therapeutics Inc.2025 Trading Recap & Growth Focused Entry Reports - Newser
Statistical indicators supporting Keros Therapeutics Inc.’s strengthQuarterly Earnings Summary & Free Weekly Watchlist of Top Performers - Newser
Keros Therapeutics Inc. Breaks Below Key Support LevelJuly 2025 Levels & Safe Entry Point Alerts - sundaytimes.kr
Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings - MarketBeat
Q3 EPS Estimate for Keros Therapeutics Lowered by Analyst - MarketBeat
Technical Bounce Expected in Keros Therapeutics Inc. Next Week2025 Year in Review & Community Consensus Picks - thegnnews.com
Keros Therapeutics Reports Strong Revenue Growth - TipRanks
XTX Topco Ltd Invests $490,000 in Keros Therapeutics, Inc. (NASDAQ:KROS) - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Cut to $20.00 by Analysts at HC Wainwright - MarketBeat
HC Wainwright Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - Defense World
William Blair Predicts Lower Earnings for Keros Therapeutics - Defense World
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
Keros Therapeutics stock price target lowered to $20 at H.C. Wainwright - Investing.com Canada
Strategic Focus on KER-065 and Leadership Changes Justify Buy Rating for Keros Therapeutics - TipRanks
Keros prioritizes KER-065, pulls plug on cibotercept - The Pharma Letter
Keros Therapeutics’ Workforce Cuts: Potential Savings vs. Strategic Risks - TipRanks
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $15 - 富途牛牛
Keros Therapeutics to discontinue cibotercept, announces COO departure - TipRanks
Keros Therapeutics, Inc. (NASDAQ:KROS) Holdings Raised by Federated Hermes Inc. - MarketBeat
Keros Therapeutics: Strategic Shift and Organizational Changes Prompt Hold Rating - TipRanks
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Keros Therapeutics Inc Azioni (KROS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER |
Apr 04 '25 |
Option Exercise |
0.30 |
49,367 |
14,810 |
302,223 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):